FDA blocked from approving abortion pills; existing drug faces strict new limits
H.R. 685 — SAVE Moms and Babies Act of 2025 · Filed by Robert Latta (R-OH) · 75 cosponsors · Introduced Jan 23, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill prohibits the FDA from approving new abortion medications and blocks investigational exemptions for them. For mifepristone (the one abortion drug already approved), it imposes strict new requirements: limiting dispensing to in-person administration in medical offices only (not pharmacies), requiring prescribers to have surgical abortion capabilities and ability to diagnose ectopic pregnancies, restricting use after 70 days gestation, and mandating detailed adverse-event reporting to the FDA and state authorities. Existing investigational studies of abortion drugs have 3 years to wind down before their exemptions are rescinded.
Why we flagged it
The bill's core mechanism is to prohibit FDA approval of new abortion drugs and impose restrictive regulatory requirements on the one already-approved medication (mifepristone). It is functionally a de facto ban on medication abortion through regulatory constraint, not an outright prohibition.
What the text implies
- The 70-day gestation limit is more restrictive than current FDA labeling (which permits use through 77 days) and may conflict with state laws permitting abortion beyond that threshold, creating legal uncertainty.
- Requiring prescribers to have surgical abortion capabilities and ability to manage severe complications may eliminate medication abortion access in settings (telehealth, rural clinics) where surgical backup is unavailable, effectively creating geographic access disparities.
The full analysis lists 4 implications of this text.
Who it affects
The bill restricts access to a medication already approved by the FDA and used by hundreds of thousands of Americans annually. It imposes prescriber requirements that will reduce the number of providers willing or able to offer medication abortion, effectively narrowing access particularly in rural and underserved areas.